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Abstract
Background: Experimental infection of malaria-naı ¨ve volunteers by the bite of Plasmodium falciparum-infected mosquitoes
is a preferred means to test the protective effect of malaria vaccines and drugs. The standard model relies on the bite of five
infected mosquitoes to induce malaria. We examined the efficacy of malaria transmission using mosquitoes raised
aseptically in compliance with current Good Manufacturing Practices (cGMPs).
Methods and Findings: Eighteen adults aged 18–40 years were randomized to receive 1, 3 or 5 bites of Anopheles stephensi
mosquitoes infected with the chloroquine-sensitive NF54 strain of P. falciparum. Seventeen participants developed
malaria; fourteen occurring on Day 11. The mean prepatent period was 10.9 days (9–12 days). The geometric mean
parasitemia was 15.7 parasites/mL (range: 4–70) by microscopy. Polymerase chain reaction (PCR) detected parasites 3.1
(range: 0–4) days prior to microscopy. The geometric mean sporozoite load was 16,753 sporozoites per infected mosquito
(range: 1,000–57,500). A 1-bite participant withdrew from the study on Day 13 post-challenge and was PCR and smear
negative.
Conclusions: The use of aseptic, cGMP-compliant P. falciparum-infected mosquitoes is safe, is associated with a precise
prepatent period compared to the standard model and appears more efficient than the standard approach, as it led to
infection in 100% (6/6) of volunteers exposed to three mosquito bites and 83% (5/6) of volunteers exposed to one mosquito
bite.
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Introduction
Experimental infection of malaria-naı ¨ve volunteers by the bite
of Plasmodium falciparum-infected mosquitoes has been a preferred
means to test the protective effect of malaria vaccine and drug
candidates in malaria-naı ¨ve volunteers. Experimental induction of
malaria by the bite of infected mosquitoes has been reported in the
literature for nearly 90 years [1,2]. The conduct of challenge trials
is complicated by the need for a mosquito insectary and expertise
of personnel in rearing the insects, the transport of infected
mosquitoes to the study site, and tight restrictions on mosquito-
rearing and infection to coincide with vaccine or drug adminis-
tration. If sporozoites could be manufactured, vialed, and
transported to clinical trial centers around the world, and used
to infect volunteers by needle and syringe inoculation, this would
dramatically increase the capacity to assess new anti-malaria
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13490vaccine and drug candidates. Such capacity is of critical
importance as the need for malaria challenge facilities is expected
to grow with the advent of new malaria vaccine constructs and
new antimalarial drugs [3].
Despite the current challenges to using infected mosquitoes for
challenge, recent data from 532 volunteers has demonstrated that
experimental infection of malaria-naı ¨ve volunteers is safe and
reliable [4], and more than 1450 volunteers have been challenged
by this method during the past 25 years [5]. The challenge model
effectively predicted clinical efficacy for the RTS,S malaria
vaccine prior to clinical trials in malaria-endemic areas [6].
Except in settings with very high malaria transmission intensity,
individuals are rarely bitten by more than one infected mosquito
per night under natural conditions. Malaria sporozoite challenge
studies have traditionally relied upon the bites of five infected
mosquitoes to induce malaria [7,8,9,10]. Fewer bites by mosqui-
toes raised in non-sterile conditions, have not reliably induced
malaria in volunteers [11,12,13], and increased bites may provide
an unrealistic and overwhelming challenge in which even
irradiated-sporozoite immunized volunteers fail to be protected
from malaria challenge [14].
The aseptic rearing of P. falciparum sporozoite-infected mosqui-
toes in compliance with current Good Manufacturing Practices
(cGMPs) and the demonstration that these mosquitoes contain
fully infectious sporozoites that can transmit malaria infection is
the first step toward developing a method to manufacture vialed
sporozoites for parenteral administration. Furthermore, use of
such mosquitoes to infect volunteers may reduce the variability of
sporozoite load among mosquito lots, improve reproducibility of
the pre-patent period and infection rate, and decrease the
theoretical risk to human volunteers of infection by co-infecting
microorganisms in the mosquito salivary glands. While laboratory-
reared Anopheles typically have higher salivary gland sporozoite
loads than wild-caught anophelines [15], they have highly variable
loads [16,17] which may result in a variable inoculum of
sporozoites with each mosquito bite [17]. An increase in
sporozoite and liver stage parasite burden may decrease the
prepatent period [12,18], and a decrease in burden could increase
the prepatent period. In our experience A. stephensi mosquitoes
reared in standard insectaries are contaminated with bacteria and
fungi, which may reduce mosquito fitness and infection by the
malaria parasite. There is no evidence from challenge studies that
coincidental transmission of these agents to humans occurs but
there is the theoretical risk of mechanical transmission of fungi and
bacteria from the proboscis during feeding by traditionally-reared
mosquitoes.
The production of aseptic mosquitoes, reared in compliance
with cGMPs has been established for the manufacture of the
metabolically active, non-replicating (radiation attenuated), asep-
tic, purified, vialed P. falciparum sporozoites (PfSPZ) used in the
PfSPZ Vaccine [19,20]. In this study we have used non-irradiated
mosquitoes manufactured by the identical procedure as those used
for the PfSPZ Vaccine to establish the infectivity of aseptic
sporozoites transmitted by aseptically reared mosquitoes. We
sought to determine the minimum number of A. stephensi bites
required to safely achieve 100% volunteer infection with special
attention to prepatent periods, sporozoite loads and parasitemia.
Methods
Objectives
The primary objective of this study was to evaluate the safety
and tolerability of a new human malaria challenge model using
aseptic A. stephensi mosquitoes infected with the chloroquine-
sensitive NF54 isolate of P. falciparum and reared in compliance
with cGMPs. Secondary objectives were to investigate the
minimum number of A. stephensi bites required to safely achieve
100% volunteer infectivity, to study the character of the malaria
infection and ascertain any differences between infection conferred
by aseptic sporozoites and that described in traditional malaria
challenge events, and to assess the role of molecular diagnostic
techniques for accurate real-time diagnosis of P. falciparum
infection. The protocol for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1.
Study population and design
The clinical study was conducted at the Center for Vaccine
Development (CVD), at the University of Maryland School of
Medicine in Baltimore, Maryland. Eighteen malaria-naive adults
aged 19–39 years were randomized in a 1:1:1 ratio to receive 1, 3
or 5 bites of A. stephensi mosquitoes infected with P. falciparum
(Figure 1). Participants were randomized by an online random
allocation sequence generated by the EMMES Corporation and
accessed by the study nurse coordinator. Once randomized, study
personnel administering the challenge were not blinded as to the
bite assignation. Participants were previously screened for good
health and submitted blood for laboratories including hepatitis and
HIV serologies and urine for pregnancy testing if applicable.
Baseline complete blood counts (CBC), creatinine, glucose,
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) were screened and only volunteers with tightly defined
normal values were enrolled. Additionally, volunteers were pre-
screened for those with significant cardiovascular risk (i.e., .10%,
5 year risk)[21]. Risk factors include sex, age (years), systolic blood
pressure (mm Hg), smoking status (current vs. past or never), body
mass index (kg/mm
2), reported diabetes status, or current
treatment for raised blood pressure. A 12-lead ECG was
performed and read by a staff cardiologist. Exclusion criteria
included known history of malaria infection, long-term residence
(.5 years) in a malaria-endemic area, travel to a malaria-endemic
area within the previous 6 months, and splenectomy.
Ethics
The trial was conducted in compliance with the Declaration of
Helsinki. All volunteers signed an informed consent form after
hearing a detailed explanation of the study and passing a written
examination designed to ascertain if they understood the risks of
malaria infection. Study protocols were reviewed and approved by
institutional review boards of the University of Maryland and the
National Institute of Allergy and Infectious Diseases/Division of
Microbiology and Infectious Diseases. The trial was monitored by
PPD, Inc. (Wilmington, NC).
Dosage, Preparation and Administration of Study
Product
A. stephensi mosquitoes infected with P. falciparum parasites of the
NF54 strain were used for challenge utilizing methods developed
by Sanaria, Inc (Rockville, MD). Briefly, eggs from A. stephensi
mosquitoes were disinfected and placed in a custom medium for
growth to pupae. Adult female mosquitoes were fed P. falciparum
gametocytes in transfusion-quality human erythrocytes and serum.
A proportion of the eggs, pupae, blood meal, and mosquitoes were
cultured to assess for microbial growth. Only confirmed aseptic
material was used in the study. Mosquitoes were transported under
aseptic conditions to CVD and maintained aseptically at
appropriate temperature and humidity. Prior to human challenge,
Aseptic Challenge Model
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cylindrical cardboard container with a mesh top. The mosquitoes
were placed on exposed forearms and allowed to feed for 5 minutes,
after which they were removed and dissected to determine whether
the mosquito had 1) fed and 2) salivary gland sporozoites. A
mosquito would be categorized as ‘‘fed’’ if blood was found within
the mid-gut after challenge. Entomologist also dissected out the
paired salivary glands and quantified the sporozoite load. If
necessary, additional mosquitoes were used until the requisite
numbers of infected mosquitoes had fed upon the participant. The
techniques utilized were identical to those used as part of the
development of the metabolically-active, replication deficient,
whole-organism malaria vaccine (PfSPZ Vaccine).
Quantification of salivary gland sporozoite load
By convention, the number of sporozoites present in mosquito
salivary glands is categorized as: 0 (no sporozoites), 1 (1–10), 2 (11–
100), 3 (101–1000), 4 (.1000) [17]. In this study, a hemocytom-
eter was used to quantify the sporozoite load per mosquito
(Chakravarty et al., manuscript in preparation). The method used
had a lower limit of detection of 250 sporozoites per mosquito.
Post-challenge Assessment
Participants were monitored for 30 minutes after challenge and
asked to maintain symptom diaries until Day 7. They were
evaluated on Days 5–7 and were admitted to an in-patient ward
on Day 8 prior to the expected time of blood stage parasitemia.
Daily histories, vital signs, physical exams, blood smears and real-
time quantitative polymerase chain reaction (RTQ-PCR) assays
were performed. Asymptomatic individuals were provided with
pagers for rapid contact, allowed to leave the ward during the day,
and return in the evenings for evaluation. Symptomatic or
parasitemic individuals remained on the ward under clinical
supervision. After confirmation of parasitemia by microscopy,
volunteers received 1500 mg chloroquine base as standard first
line therapy over 48 hours. The volunteers were discharged after
documentation of three sequential negative blood smears and were
followed weekly for 4 weeks followed by a final visit on Day 56.
Assessment of safety and tolerability
All adverse events were graded for 1) severity (mild-easily
tolerated, moderate-interfered with daily activity, or severe-
prevented daily activity) and 2) relatedness (associated or not
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0013490.g001
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.99.5–100.4uF; moderate, .100.4–102.2uF; and severe,
.102.2uF), and erythema/induration (mild, 0–22 mm; moderate,
21–50 mm; and severe, .50 mm). The local challenge site was
assessed and general solicited symptoms or signs evaluated. Local
reactions that persisted beyond Day 2 were recorded as adverse
events based on the reasoning that erythema, pruritis and
induration are normal responses to mosquito bites during two
days post- exposure. Solicited symptoms related to the malaria
challenge (Days 2–7) (Table 2) and related to blood stage malaria
began on Day 8 (Table 3) and continued for the duration of the
volunteer follow-up or until a malaria diagnosis. Any other signs or
symptoms were considered to be unsolicited.
Due to an adverse cardiac event that occurred in the setting of
malaria challenge at another challenge center, ECGs and troponin
levels were done on day 3 and 10 after the malaria diagnosis for
exploratory purposes [22]. Of note, this cardiac event consisting of
chest pain at rest in a young female volunteer occurred in the
setting of malaria vaccine administration, subsequent active
malaria infection and malaria eradication using RiametH. The
temporal association of the event with malaria challenge was likely
circumstantial but the exact etiology of the chest pain remains
unclear. Safety labs including a CBC, creatinine, glucose, AST
and ALT were drawn on all days of a positive malaria smear, the
duration of treatment and at each of four weekly follow-ups
thereafter.
Malaria Diagnostics
Blood smears. Beginning on Day 5, daily blood smears
were performed to monitor for the presence of blood stage
parasites. Blood smear intervals were decreased to every 8–
12 hours if participants developed signs or symptoms consistent
with malaria, until a diagnosis was established. Ten mLo fb l o o d
were placed on a microscope slides in a 162 cm rectangle, heat-
fixed and Giemsa-stained for P. falciparum parasites. Two trained
investigators, blinded to randomization results, examined five
separate passes along the 1 cm axis using the 100x oil immersion
lens of calibrated microscopes. This was doubled to ten passes for
symptomatic individuals. The five passes performed by two
separate microscopists on different areas of the smear examined a
total of 0.9–1.1 mL of blood. Parasites were quantified per mL.
For positive smears, or if questions or discrepancies arose, a third
trained investigator (MBL) was called on to read and quantify
parasite burden. The minimum criterion for acceptance of a
positive smear was identification of two unquestionable P.
falciparum parasites confirmed by at least one investigator and
MBL. All therapeutic decisions were based on the results of a
positive blood smear.
Real-time quantitative DNA polymerase chain reaction
(RTQ-PCR). To evaluate and optimize methods for early
molecular diagnosis of P. falciparum malaria in challenge trials,
RTQ-PCR was performed on 0.5 mL of venous blood collected
contemporaneously with blood smears using published methods
with minor adaptation [23]. Standard curve cell counts were
determined by FacsCaliber flow cytometer. PCR primers were
based on the published sequence of the highly conserved [24],
stage specific [25] P. falciparum 18S ribosomal RNA gene. Primer
sequences were identical to the corresponding sequence of the
NF54 strain. Samples were blinded and assays were run daily.
Each sample was run in triplicate along with a water control. The
data were analyzed using the Applied Biosystem 7300 Absolute
Quantification Software. The assay sensitivity was determined to
be 40 parasites/mL. Results were not utilized for therapeutic
decisions.
Statistics
The study was designed to be a proof-of-concept study and was
not powered for statistically significant comparisons. Each subject’s
exposure to the randomized number of bites (1, 3, or 5) was
considered a separate Bernoulli trial with ‘success’ defined as a
positive malaria smear within 56 days of exposure. The agreement
of RTQ-PCR to the blood smear analysis was conducted and
presented using Pearson’s Correlation as well as a linear regression
analysis. These analyses were conducted on matched, paired
smear and RTQ-PCR test results utilizing SAS (version 9.1.3,
Cary, N.C.). The study database was managed by the EMMES
Corporation (Rockville, MD).
Results
Study Population and Malaria Challenge Event
Eighteen adults aged 19–39 years (mean: 29 years) underwent
challenge in March2009 bythe bite of 1,3 or 5 bites ofP. falciparum-
infected mosquitoes on the same day (Table 1). Participants
randomized to receive 1, 3 or 5 bites required a mean presentation
of 2, 5.7 or 14.5 challenge mosquitoes, respectively. In total, 49% of
femaleAnophelesmosquitoes presented forchallenge ingesteda blood
meal and approximately 75% of the fed mosquitoes had detectable
salivary gland sporozoites.
Sporozoite load results
Mosquitoes were dissected immediately and the total sporozoite
density determined. The geometric mean sporozoite load was
16,753 (range: 1,000 to 57,500) sporozoites per infected mosquito
and did not vary appreciably between bite groups (Table 1). No
infected mosquitoes with fewer than 1,000 sporozoites were found.
Post-Challenge Safety Assessment
Solicited adverse events were collected on local reactogenicity to
the challenge on Days 2–7 (Table 2). No severe adverse events
were reported. Fifteen local reactogenicity events in ten volunteers
were associated with the challenge. All symptoms were rated as
mild and included erythema, induration and pain at the challenge
site. There were 29 solicited adverse events with only one related
to the malaria challenge event (malaise). Three mild events
(malaise, myalgia, and arthralgia) and one moderate (arthralgia)
event occurred on Day 6 in two volunteers from the 5 bite group,
and were deemed associated with impending malaria infection and
not to the challenge event itself. The remaining solicited events
related to self-limited viral gastroenteritis experienced by several
participants before the inpatient portion of the trial. Six unsolicited
adverse events (pruritis) were reported during the post-challenge
period, five of which were deemed mild and one moderate.
Malaria Event
Seventeen participants developed parasitemia, fourteen occur-
ring on Day 11, with a mean pre-patent period of 10.9 days (9–12
days). The eighteenth participant (1 bite group) withdrew from the
study on Day 13, and was PCR and smear negative on Day 13 at
which point she was treated with chloroquine. Interestingly, it took
exposure to 9 mosquitoes for one to successfully feed on this
participant (Table 1). Six participants had mild symptoms including
malaise, headache, nausea, and diarrhea preceding malaria
diagnosis by a mean of 4.3 days (range 3–6). No individuals had
temperatures greater than 99.9uF before detection of parasitemia.
Most participants (15/18, 83.3%) reported at least one adverse
event. Fifteen individuals developedan elevated temperature, five of
which were graded as severe (.102.2uF) with a mean duration of
2.2 days. The most common solicited adverse events included fever
Aseptic Challenge Model
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chills/rigors (n=11) (Table 3). All other solicited adverse events
were graded as mild or moderate. Solicited symptoms peaked 48–
72 hours after diagnosis coinciding with chloroquine clearance of
parasitemia and persisted for a mean of 5 days (2–11 days).
Laboratory abnormalities were noted in 12 of 17 (71%)
individuals (Table 4). Abnormalities in liver transaminases (AST
and ALT), platelets and white blood cell count were most
commonly noted. One individual in the 3 bite group had severe,
albeit clinically insignificant, thrombocytopenia (84,000/mm
3) and
three participants had mild or moderate thrombocytopenia. Five
participants (27.8%) had abnormal AST or ALT levels with peak
values of 202 IU/mL and 124 IU/mL. Six participants developed
leukopenia. No hypoglycemic events or renal abnormalities were
Table 1. Demographic information and study results by group and by malaria infectivity.
Target
Bites (n)
Age
(years) Sex(%)
Body
mass
index
Total
mosquitoes
presented
(mean per
person)
Total mosquitoes
taking blood
meal
a (% of total
presented)
Total Infected
Mosquitoes
b (%
of those taking a
blood meal)
Geometric
mean
sporozoites
c
Mean
Pre-
patent
period
in days
Geometric
mean
parasite
density
per ml
Mean day of
initial PCR
detection
d
Infected (17)
1 bite (5) 28.8 2F (40) 31.8 10 (2) 6 (60) 5 (83) 15,028 11.2 9.6 8.6
range (19–39) (24–45) (1–3) (3,000–41,000) (11–12) (4–21) (7–11)
3 bite (6) 28.7 1F (17) 28.5 40 (6.7) 26 (65) 18 (69) 16,616 10.8 15.5 7.2
range (20–34) (21–49) (5–10) (2,500–57,500) (10–11) (8–32) (7–8)
5 bite (6) 31.1 2F (33) 33.3 87 (14.5) 39 (45) 30 (77) 16,988 10.7 24.1 7
range (23–39) (28–46) (9–27) (1,000–56,000) (9–11) (8–70) (7)
Uninfected (1)
1 bite
e (1) 21 1F(100) 39 9 1 (11) 1 (100) 22,000 N/A N/A N/A
Total (18) 29 6F (33) 33 146 72 (49) 54 (75) 16,753 10.9 15.7 7.5
range (19–39) (21–49) (1,000–57,500) (9–12) (4–70) (7–11)
aMosquitoes that were presented in challenge and subsequently had evidence of blood in the midgut as determined by on-site observation through a dissection
microscope.
bFed mosquitoes that had sporozoites in the salivary glands as determined by dissection after the challenge had been complete.
cThe geometric mean was calculated only on fed, infected mosquitoes.
dThe mean day of initial PCR detection refers to day post-challenge.
eThis volunteer who did not become infected before treatment was unique in that the first 8 mosquitoes presented to the volunteer did not feed.
doi:10.1371/journal.pone.0013490.t001
Table 2. Signs and solicited symptoms during the 7-day follow-up periods after challenge.
Study Group
All Groups 1 Bite (N=5) 3 Bites (N=6) 5 Bites (N=6)
None (%) Mild (%) Mod (%) None (%) Mild (%) Mod (%) None (%) Mild (%) Mod (%) None (%) Mild (%) Mod (%)
Local
Erythema 8 (44.4) 10 (55.6) 0 (0) 3 (50) 3 (50) 0 (0) 2(33.3) 4 (66.7) 0 (0) 3 (50) 3 (50) 0 (0)
Induration 14 (77.8) 4 (22.2) 0 (0) 5(83.3) 1(16.7) 0 (0) 4(66.7) 2 (33.3) 0 (0) 5 (83.3) 1 (16.7) 0 (0)
Site Pain 17 (94.4) 1 (5.6) 0 (0) 6 (100) 0 (0) 0 (0) 6 (100) 0 (0) 0 (0) 5 (83.3) 1 (16.7) 0 (0)
Systemic
Malaise 10 (55.6) 5 (27.8) 3 (16.7) 3 (50) 2(33.3) 1 (16.7) 4(66.7) 1 (16.7) 1 (16.7) 3 (50) 2 (33.3) 1 (16.7)
Myalgia 15 (83.3) 1 (5.6) 2 (11.1) 5 (83.3) 0 (0) 1 (16.7) 6 (100) 0 (0) 0 (0) 4 (66.7) 1 (16.7) 1 (16.7)
Arthralgia 14 (77.8) 2(11.1) 2 (11.1) 5 (83.3) 1(16.7) 0 (0) 6 (100) 0 (0) 0 (0) 3 (50) 2 (33.3) 1 (16.7)
Nausea 13 (72.2) 2 (11.1) 3 (16.7) 4 (66.7) 0 (0) 2 (33.3) 5(83.3) 1 (16.7) 0 (0) 4 (66.7) 1 (16.7) 1 (16.7)
Abd. pain 16 (88.9) 2 (11.1) 0 (0) 5 (83.3) 1(16.7) 0 (0) 6 (100) 0(0) 0 (0) 5 (83.3) 1 (16.7) 0 (0)
Diarrhea 15 (83.3) 3 (16.7) 0 (0) 6 (100) 0 (0) 0 (0) 4(66.7) 2 (33.3) 0 (0) 5 (83.3) 1 (16.7) 0 (0)
Fever 18 (100) 0 (0) 0 (0) 6 (100) 0 (0) 0 (0) 6 (100) 0 (0) 0 (0) 6 (100) 0 (0) 0 (0)
Urticaria 18 (100) 0(0) 0 (0) 6 (100) 0 (0) 0 (0) 6 (100) 0 (0) 0 (0) 6 (100) 0 (0) 0 (0)
Headache 14 (77.7) 3 (16.7) 1 (5.6) 5 (83.3) 0 (0) 1 (16.7) 4(66.7) 2 (33.3) 0 (0) 5 (83.3) 1 (16.7) 0 (0)
doi:10.1371/journal.pone.0013490.t002
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ECGs and troponin levels were normal.
Malaria diagnostics
The geometric mean parasite density at diagnosis as determined
by blood smear analysis was 15.7 parasites/mL. A ‘‘dose response’’
was noted within the bite groups with the following geographic
mean parasite densities for the 1, 3 and 5-bite groups (9.6, 15.5
and 24.1 parasites/mL) although the differences were not signif-
icant. While the mean pre-patent period was 10.9 days, the mean
incubation period was 8.6 days. Detection by PCR was noted a
mean of 3.1 days before positive smear results. There were no false
positive or definitive false-negative PCR results although PCR
failed to detect parasitemia in one individual (1 bite group) until
the day of blood smear diagnosis. Removing this participant, PCR
detection preceded blood smear diagnosis by 2–4 days (mean 3.3
days) (Figure 2). Furthermore, the dynamics of parasite growth by
PCR, although limited by once daily monitoring, were quite
similar for each bite group (Figure 3). Parasites were detected by
blood smear for a mean of 1.94 days after initiation of chloroquine
treatment and by PCR for a mean of 1.35 days after chloroquine
initiation. There was a strong, statistically significant association
between smear and PCR results (Pearson coefficient =0.841, 95%
CI [0.763, 0.981], linear regression analysis R
2=0.714, p=0.002).
Discussion
The use of P. falciparum sporozoite-infected A. stephensi
mosquitoes reared aseptically under cGMPs is safe, efficiently
and reliably transmits malaria, and is associated with a very precise
pre-patent period. This first trial was a proof-of-principle study,
establishing that these mosquitoes are viable and capable of
transmitting malaria to volunteers at least as efficiently as
mosquitoes reared under conventional conditions. Moreover, a
precise prepatent period of 11 days was demonstrated in this study
along with a determination that the quantity of mosquito bites
required to confer malaria in 100% of the volunteers is at most, 3
bites, and may be one bite.
The traditional malaria challenge technique without the benefit
of asepticity is safe and predictably transmits malaria [4]. The
aseptic malaria challenge model appears similarly safe and well
tolerated and advances the science of malaria challenge as well as
the protection of human subjects. Symptom severity was generally
mild to moderate with only five volunteers suffering a severe
symptom (i.e. fever .102.2uF) defined by criteria consistent with
FDA guidelines. The symptoms associated with malaria peaked 2–
3 days after diagnosis coinciding with clearance of parasites, and
thus probably represent an inflammatory response to the clearing
infection. The solicited symptoms noted in this trial were generally
mild and even less in frequency than previously reported (Table 4)
[4]. Similarly, laboratory abnormalities were transient, and mild to
moderate in grade with the exception of a single case of severe
thrombocytopenia (84,000/mm
3); a level that is not associated
with an increased risk of bleeding. Leukopenia was noted in 41%
of participants with malaria and occurred a mean of 2.1 days (1–4
days) after onset of detectable parasitemia by blood smear, and
lasted between 1 and 8 days [4,12,26]. The severity of laboratory
abnormalities did not appear to correlate with the bite quantity or
sporozoite load within the biting mosquitoes. None of the
Table 3. Signs and solicited symptoms during the malaria event by bite group.
Study Group
Past
Resultsa
(N=47)
Current
Resultsb
(N=17) 1 Bite (n=5) 3 Bites (n=6) 5 Bites (n=6)
Symptoms N (%) N (%)
None N
(%)
Mild N
(%)
Mod N
(%)
Severe
N (%)
None N
(%)
Mild N
(%)
Mod N
(%)
Severe
N( % )
None N
(%)
Mild N
(%)
Mod N
(%)
Severe
N (%)
Fever
c 47 (100) 15 (88) 0 (0) 3(60) 2(40) 0 (0) 1(17) 1(17) 2(33) 2 (33) 1 (17) 1 (17) 1 (17) 3 (50)
Headache 47 (100) 12 (71) 2(40) 1(20) 2(40) 0 (0) 1(17) 3(50) 2(33) 0 (0) 1 (17) 3 (50) 2 (33) 0 (0)
Malaise 44 (94) 12 (71) 3(60) 0 (0) 2(40) 0 (0) 1(17) 2(33) 3(50) 0 (0) 1 (17) 4 (67) 1 (17) 0 (0)
Chills 40 (85) 11 (65) 4(80) 1(20) 0 (0) 0 (0) 3 (50) 2(33) 2(33) 0 (0) 0 (0) 3 (50) 3 (50) 0 (0)
Myalgia 38 (81) 12 (71) 2(40) 0 (0) 3(60) 0 (0) 2 (33) 2(33) 2(33) 0 (0) 1 (17) 4 (67) 1 (17) 0 (0)
Nausea 29 (62) 6 (35) 0 (0) 2(40) 1(20) 0(0) 4 (67) 1(17) 1(17) 0 (0) 4 (67) 2 (33) 0 (0) 0 (0)
Dizziness 24 (51) 5 (29) 0 (0) 0 (0) 0 (0) 0 (0) 2 (33) 3(50) 1(17) 0 (0) 5 (83) 1 (17) 0 (0) 0 (0)
Arthralgia 17 (36) 10 (59) 2(40) 0 (0) 3(60) 0 (0) 2 (33) 0 (0) 3(50) 0 (0) 2 (33) 2 (33) 2 (33) 0 (0)
Abd. pain 17 (36) 5 (29) 3(60) 1(20) 1(20) 0 (0) 5(83) 0 (0) 1(17) 0 (0) 3 (50) 3 (50) 0 (0) 0 (0)
Diarrhea 12 (26) 5 (29) 4(80) 2(40) 0 (0) 0 (0) 4(67) 2(33) 0 (0) 0 (0) 5 (83) 1 (17) 0 (0) 0 (0)
Cough 9 (19) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Vomiting 6 (13) 3 (13) 4(80) 1(20) 0 (0) 0 (0) 6(100) 0 (0) 0 (0) 0 (0) 4 (67) 2 (33) 0 (0) 0 (0)
SOB
d ND 2 (12) 6(100) 0 (0) 0 (0) 0 (0) 5 (83) 1(17) 0 (0) 0 (0) 5 (83) 1 (17) 0 (0) 0 (0)
Stamina
d ND 3 (18) 4 (80) 1(20) 0 (0) 0(0) 4 (67) 2(33) 0 (0) 0(0) 6(100) 0 (0) 0 (0) 0 (0)
Chest pain ND 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0(0) 0 (0)
Urticaria ND 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
aPreviously published literature on the symptoms associated with the malaria event in the traditional malaria challenge[4].
bSummary data of findings noted at the University of Maryland at Baltimore.
cA fever was defined as .99.5uF orally.
dSOB refers to shortness of breath; stamina refers to change in exercise tolerance.
doi:10.1371/journal.pone.0013490.t003
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Organization criteria for severe malaria [27].
The traditional challenge methodology relies on the bite of five
mosquitoes to reliably transmit malaria to 100% of volunteers.
Utilizing mosquitoes raised aseptically under cGMPs, all partic-
ipants in the 3 and 5 bite groups and 5 of 6 volunteers in the 1 bite
group developed malaria. One volunteer withdrew from the study
on day 13 and was treated with chloroquine before developing
parasitemia. Excluding this volunteer, whose ultimate infection
status is unknown, 100% infectivity was achieved with a single
bite. The number of mosquitoes required to achieve a successful
blood feed varied per individual. In instances where a higher
number of mosquitoes were required to achieve a successful blood
feed, it is possible that the total number of mosquitoes to which the
volunteers were exposed was underestimated as mosquitoes can
inoculate sporozoites as they probe for blood, even if they did not
take a blood meal. However, of the volunteers randomized to the
one bite arm, two were exposed to the bite of only one mosquito
and the rest were exposed to only two or three mosquitoes (total of
10 mosquitoes for infecting 5 volunteers, Table 1) before achieving
a successful blood feed indicating that #3 mosquitoes are required
to achieve malaria infection using this technique. It should be
noted that all other studies have used the same criteria for a
successful blood feed. Thus, regardless of probing without feeding,
our data are distinct from the other studies, despite use of similar
methodology.
Of the 17 participants who were infected, 14 (82%) developed a
positive blood smear on Day 11 (range 9–12) after challenge. This
compares favorably with previous published results where 18/47
(38%) participants developed malaria on Day 11 (range 9–14,
mean 10.52 days) but the pre-patent period was more variable.
Increased sporozoite inoculation and liver burden could result in
reduced prepatent periods [18] or prolonged parasitemias [28].
Conversely, the physical characteristics of the mosquito salivary
duct may limit the number of sporozoites that can be inoculated
during probing and feeding [29]. In the P. yoelli model, sporozoite
injection has proven to be highly variable ranging from 0–1,297
Table 4. Laboratory abnormalities recorded during the malaria event.
Study Group
Parameter/unit Grade Range 1 Bite (%) 3 Bites (%) 5 Bites (%)
AST (IU/L) None 0–40 4 (80) 4 (67) 3 (50)
Mild 41–99 1 (20) 2 (33) 1 (17)
Moderate 100–199 0 (0) 0 (0) 2 (33)
Severe $200 0 (0) 0 (0) 0 (0)
ALT (IU/L) None 0–55 (=) 0–40 (R)
a 5 (100) 4 (67) 3 (50)
Mild 56–137 (=) 41–99 (R) 0 (0) 2 (33) 1 (17)
Moderate 138–274 (=) 100–199 (R) 0 (0) 0 (0) 2 (33)
Severe $275 (=) $200 (R) 0 (0) 0 (0) 0 (0)
Hemoglobin (g/dL) None 12.5–17.0 (=) 11.5–15.0 (R) 5 (100) 5 (83) 6 (100)
Mild 10.6–12.4 (=) 11.1–11.4 (R) 0 (0) 1 (17) 0 (0)
Moderate 10,0–10.5 (=) 9.6–10.0 (R) 0 (0) 0 (0) 0 (0)
Severe ,10.0 (=) #9.5 (R) 0 (0) 0 (0) 0 (0)
WBC (x 10
3/mm
3) None 4.0–10.5 3 (60) 3 (50) 4 (67)
Mild 2.5–3.9 2 (40) 2 (33) 2 (33)
Moderate 1.5–2.4 0 (0) 1 (17) 0 (0)
Severe ,1.5 0 (0) 0 (0) 0 (0)
Platelets (x 10
3/mm
3) None $140 5 (100) 2 (33) 6 (100)
Mild 125–139 0 (0) 0 (0) 0 (0)
Moderate 100–124 0 (0) 3 (50) 0 (0)
Severe 20–99 0 (0) 1 (17) 0 (0)
a(=) represents males and (R) represents females.
doi:10.1371/journal.pone.0013490.t004
Figure 2. Time to infection of volunteers measured by blood
smear and PCR. The time to infection of all volunteers (pooled
exposed to 1, 3 and 5 infectious bites) measured by blood smear (solid
line, median time to infection =11 days) and PCR (dashed line, median
time to infection =8 days) was significantly different (p#0.001, Mantel-
Cox test).
doi:10.1371/journal.pone.0013490.g002
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13490Figure 3. Dynamics of parasite growth in volunteers after challenge. Each line shows the parasite density in an individual volunteer as
measured by PCR after being bitten by 1 (top), 3 (middle) or 5 (bottom) Plasmodium falciparum-infected Anopheles stephensi mosquitoes. All
volunteers were treated on day 11 (vertical dashed line on each panel) when parasites were detected by blood smear, except for one volunteer in the
1 bite group (blue dashed line) who was positive and treated on day 12, one volunteer (grey dashed line) in the 3 bite group who was positive and
treated on day 10, and one volunteer (red dashed line) in the 5 bite group who was positive and treated on day 9. Data are presented until last
positive identification of parasites in the blood by PCR. Values shown as 1 on the log scale were negative.
doi:10.1371/journal.pone.0013490.g003
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gland quantity [30]. Therefore, increased numbers of sporozoites
per mosquito may not translate into increased sporozoites
inoculated. Complicating interpretation, the traditional method
of determining sporozoite loads is imprecise, relying upon
qualitative estimation of total sporozoites on salivary glands
squashes, with gland scores graded from 0 to 4+ [17]. In virtually
all previous studies, mosquitoes with a gland score of $2+ (11–100
sporozoites) were considered infectious [7]. Utilizing a more
precise counting technique, 16,753 sporozoites per mosquito
(range 1,000–57,500) were present in the challenge mosquitoes.
Our data indicate that mosquitoes raised aseptically in compliance
with cGMPs can successfully transmit malaria to 100% of
participants through the bite of 3, and likely 1, rather than 5
mosquito bites, and suggest they may lead to a more precise pre-
patent period. The mosquitoes used in this study had more
sporozoites than those used in most other studies. Thus, it is
possible that the infectivity of 1 and 3 infected mosquitoes may
have been due to an increased sporozoite inoculum when
compared to traditionally-raised mosquitoes, but experimental
data in P. yoelii [30] do not support this interpretation.
The use of PCR to achieve diagnosis earlier in malaria
challenge studies is attractive, but it also carries risks. A false
negative or false positive result in a small challenge trial of a
malaria vaccine could profoundly alter study results. There were
no false positive results in our preliminary use of this technique.
While the ability to detect low-level parasitemia days before blood
smear detection could, theoretically, avert symptoms associated
with malaria, we did not find a correlation between PCR and
symptom onset (data not shown). Moreover, the severity of
symptoms increased once therapy was initiated and peaked after
48–72 hours when parasites were no longer detectable. Perfor-
mance of the PCR assay could be increased to every 8–12 hours to
enhance detection, but PCR is, currently, more labor-intensive
procedure than is the reading of blood smears, and would require
round-the-clock staffing in a challenge setting. Further study of
diagnostic PCR in the context of volunteer challenges is required
to fully document the pre-test specificity of the assay.
The development of a metabolically active, non-replicating
(radiation attenuated) P. falciparum sporozoite vaccine is based on
the successful immunization of volunteers by the bite of irradiated,
non-aseptic mosquitoes [7]. It has been hypothesized that the
contaminants, including bacterial and fungal material, accompa-
nying these mosquitoes may provide some adjuvant effects that
enhance sporozoite-induced immunity. Our study does not give
any indication of the immunogenicity of the sporozoites
administered by the bite of aseptically-reared mosquitoes, but
establishing that the sporozoites produced under aseptic conditions
remain fully virulent and capable of eliciting malaria is nonetheless
important data for the effort to develop a metabolically active,
non-replicating whole sporozoite P. falciparum vaccine, which is
produced in aseptic A. stephensi mosquitoes using the same
methodology.
Now that the aseptic malaria challenge model has been
established with the NF54 strain of P. falciparum, which has
historically been utilized in malaria challenge studies, we plan to
develop challenges with additional P. falciparum strains. The genetic
diversity of P. falciparum poses significant challenges to vaccine
development [31], and the development of a heterologous
challenge model will permit assessment of the ability of vaccine
candidates to provide protection against genetically diverse
parasites and of anti-malarial drugs to prevent malaria caused
by P. falciparum of differing drug sensitivities.
The data from this trial demonstrate that aseptic sporozoites can
transmit malaria. This is the first step toward developing and
assessing the infectivity of aseptic, purified, cryopreserved P.
falciparum sporozoites administered by needle and syringe to infect
volunteers rather than relying on the bite of a mosquito. This
would allow institutions without the capability of rearing infectious
mosquitoes to safely, and reliably conduct malaria challenge trials,
and such a study is being planned. Ultimately, our goal is to have
multiple strains of P. falciparum parasites that are cryopreserved and
packaged for transport to be used by institutions worldwide for
testing malaria vaccines and pharmacologic agents.
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